I'm LongbridgeAI, I can summarize articles.Daiwa issued a research report stating that BEONE MEDICINES (06160.HK) +4.400 (+1.773%) Short selling $124.15M; Ratio 26.763% again delivered better-than-expected results in the third quarter and raised its full-year guidance. Revenue increased 34% YoY to USD1.89 billion, while product revenue rose 33% YoY to USD1.86 billion, exceeding both the broker's and market expectations, mainly driven by stronger-than-expected sales of Brukinsa. Adjusted non-GAAP net profit increased 77% YoY to USD539 million. Following the second quarter, the company again raised its FY2026 guidance, with revenue guidance lifted from USD6.6 billion-USD6.8 billion to USD6.9 billion-USD7 billion, while non-GAAP operating profit guidance was raised from USD1.7 billion-USD1.8 billion to USD1.9 billion-USD2 billion. The broker believes the revised targets are easily achievable.
The broker noted that global Brukinsa sales remained strong at USD1.4 billion, up 34% YoY and 11% QoQ, driven by continued growth in the US and European Union markets. US sales reached USD1 billion, up 36% YoY and 13% QoQ, including a positive contribution of about USD50 million from order timing. European Union sales rose 33% YoY and 11% QoQ to USD218 million. TEVIMBRA sales also beat expectations, reaching USD243 million, up 28% YoY. Research and development progress was encouraging, with multiple late-stage solid tumor assets advancing toward registration studies. The broker continues to view GPC3×4-1BB as a highly differentiated asset.
The broker reiterated its Buy rating on BeOne Medicines Ltd. (ONC.US) and, based on discounted cash flow valuation, raised its 12-month TP from USD450 to USD476. The broker also raised its 2026-2028 EPS forecasts by 1% to 15%, with its 2027-2028 forecasts standing 7% to 10% above market consensus.(ad/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-10 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)
